Anthracyclines: recent developments in their separation and quantitation

被引：58

作者：

Zagotto, G ^{[1
]}

Gatto, B ^{[1
]}

Moro, S ^{[1
]}

Sissi, C ^{[1
]}

Palumbo, M ^{[1
]}

机构：

[1] Univ Padua, Dept Pharmaceut Sci, I-35131 Padua, Italy

来源：

JOURNAL OF CHROMATOGRAPHY B | 2001年 / 764卷 / 1-2期

关键词：

reviews; anthracyclines; daunorubicin; doxorubicin;

D O I：

10.1016/S0378-4347(01)00346-2

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Anthracyclines are among the most widely used anticancer agents. Notwithstanding the large efforts to develop new drugs with a better pharmaceutical profile, daunorubicin, doxorubicin, epirubicin and idarubicin are still the most used in clinical practice. Many efforts are now ongoing to reduce the side effects by using pharmaceutical formulations able to release the drug in the most appropriate way and monitoring the quantity of anthracyclines and their metabolites in the body fluids or tissues frequently and in every patient to maintain the drug concentration within the expected range. This review describes the most recent developments in the separation and quantitation of the above clinically useful drugs, together with their principal metabolites. Some less widely used derivatives will also be considered. (C) 2001 Elsevier Science B.V. All rights reserved.

引用

收藏

页码：161 / 171

页数：11

相关论文

共 44 条

[11] Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography [J].

de Bruijn, P ;

Verweij, J ;

Loos, WJ ;

Kolker, HJ ;

Planting, AST ;

Nooter, K ;

Stoter, G ;

Sparreboom, A .

ANALYTICAL BIOCHEMISTRY, 1999, 266 (02) :216-221

[12] Solution structure of iron(III)-anthracycline complexes [J].

Fiallo, MML ;

Drechsel, H ;

Garnier-Suillerot, A ;

Matzanke, BF ;

Kozlowski, H .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (15) :2844-2851

[13] An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma [J].

Fogli, S ;

Danesi, R ;

Innocenti, F ;

Di Paolo, A ;

Bocci, G ;

Barbara, C ;

Del Tacca, M .

THERAPEUTIC DRUG MONITORING, 1999, 21 (03) :367-375

[14] A SENSITIVE PROCEDURE FOR THE QUANTITATION OF FREE AND N-(2-HYDROXYPROPYL)METHACRYLAMIDE POLYMER-BOUND DOXORUBICIN (PK1) AND SOME OF ITS METABOLITES, 13-DIHYDRODOXORUBICIN, 13-DIHYDRODOXORUBICINONE AND DOXORUBICINONE, IN HUMAN PLASMA AND URINE BY REVERSED-PHASE HPLC WITH FLUOROMETRIC DETECTION [J].

FRAIER, D ;

FRIGERIO, E ;

PIANEZZOLA, E ;

BENEDETTI, MS ;

CASSIDY, J ;

VASEY, P .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 13 (4-5) :625-633

[15]

Grunaug M, 1998, Eur J Med Res, V3, P13

[16] Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis [J].

Hempel, G ;

Haberland, S ;

SchulzeWesthoff, P ;

Mohling, N ;

Blaschke, G ;

Boos, J .

JOURNAL OF CHROMATOGRAPHY B, 1997, 698 (1-2) :287-292

[17] Anthracyclines in the treatment of cancer - An overview [J].

Hortobagyi, GN .

DRUGS, 1997, 54 (Suppl 4) :1-7

[18] Determination of daunorubicin in human urine by capillary zone electrophoresis with amperometric detection [J].

Hu, Q ;

Zhang, L ;

Zhou, TS ;

Fang, YZ .

ANALYTICA CHIMICA ACTA, 2000, 416 (01) :15-19

[19] Voltammetric behaviour and determination of the anthracycline antitumor drug nogalamycin [J].

Ibrahim, MS .

ANALYTICA CHIMICA ACTA, 2000, 409 (1-2) :105-112

[20]

Katzung BG, 1997, BASIC CLIN PHARM

← 1 2 3 4 5 →